Cingulate Inc. (NASDAQ:CINGW) Short Interest Update

Cingulate Inc. (NASDAQ:CINGW) was the target of a large growth in short interest in April. As of April 30th, there was short interest totaling 11,190 shares, a growth of 405.4% from the April 15th total of 2,214 shares. Based on an average trading volume of 15,395 shares, the short-interest ratio is presently 0.7 days.

Cingulate Stock Performance

Shares of NASDAQ:CINGW traded up $0.00 during trading on Friday, reaching $0.02. 18,310 shares of the company were exchanged, compared to its average volume of 41,701. The business’s fifty day simple moving average is $0.03 and its 200-day simple moving average is $0.05. Cingulate has a 12-month low of $0.02 and a 12-month high of $0.18.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.